Navigation Links
Hyderabad To Have Asia’s First Catheter Making Uni

Hyderabad capital of Andhra Pradesh is set to house Asia's first catheter manufacturing facility, which will not only bring down the cost of catheter// based disposables but could also become an outsourcing hub for multinational companies.

Relisys Medical Devices Limited, a seven-year old company, Tuesday announced that the facility would be ready by December. Trial production is slated to begin by January next year.

The Rs.80 million facility, coming up at Manglapalli village in neighbouring Ranga Reddy district, will have the capacity to produce half a million catheter-based products annually.

To be developed as per US Food and Drug Administration (FDA) norms, it will produce 150,000 to 200,000 diagnostic catheters and 60,000 to 70,000 interventional catheters, used to pass stents to cardiac arteries.

N. Krishna Reddy, cardiologist and chairperson of Relisys, told reporters that Andhra Bank had come forward to extend a term loan of Rs.45 million for the facility.

He later told IANS that the facility would be a big boost to development of medical devices in a country, which presently produces only IV sets. "From the lowest level we are jumping to the sixth level," he said.

Krishna Reddy hoped the facility would cut the prices of catheters by 50 to 70 percent. India imports catheters at prices ranging from Rs.400 to Rs.3,000.

"This facility can not only cater to the region but also become an outsourcing hub for MNCs," he said.

The company also announced the launching of international multi-centre clinical trials of the new version of drug eluting cobalt-chromium stent coated with porous carbon-carbon nano-matrix.

Clinical trials would be conducted at nine centres in India as well as in Brazil, South Korea, Italy and Japan. The company has entered into a worldwide licensing agreement with Blue Membranes GmbH, Germany, for carbon-based drug delivery platform.

The use of porous carbon-carbon nano particle coating will eliminate the use of polymer based platform, thus completely reducing tissue inflammation and reaction (in cardiac arteries).

"Blue-Membranes will enforce the collaboration with Relisys that enables us to exploit our drug-delivery technology. We also aim to integrate manufacturing capabilities of Relisys to provide high quality manufacturing services for integrated solutions," said Soheil Asgari, CEO of Blue-Membranes.

Animal trials of this version of advanced drug eluting stent were recently completed at the Cardiovascular Research Institute, Washington.

The company had earlier completed clinical trials for its first generation drug eluting stent at All India Institute of Medical Sciences, New Delhi, Military Hospital, Pune, and Care Hospital, Hyderabad. More than 500 stents have been used since evaluation was completed six months ago.

Source: IANS


'"/>




Related medicine news :

1. Hyderabad Firm To Manufacture Tamiflu In India
2. Biotechnology Initiatives Planned In Hyderabad
3. US Consulate to Start Hyderabad Operations Next Year
4. First Vaccine Designed for Africa Cleared for Testing in Humans
5. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
6. First human clone is near
7. First Artificial Heart patient has Major setback
8. First head-to-head trials of once weekly Fosamax and Actonel therapies
9. WHO Declares Vietnam First Country to Control SARS
10. Russia Reports First SARS Case
11. Hope for First New Melanoma Treatment in Decades
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... Bill ... management industry in the coastal communities. After Tina Howe joined the team, the Bill ... happy employees, honest services at affordable rates, and giving back to the San Diego ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology: